Enterprise Value to EBITDA Ratio: Veru Inc. (VERU)
The EV/EBITDA valuation trend for Veru Inc. (VERU) shows a figure of 0.00. Veru Inc. is accelerating the launch of anti-tumor agents through partnerships with clinics. A stable staff of specialized experts and regulators supports current objectives. The business relies on the development of cutting-edge cancer drugs and weight control agents that preserve muscle tissue.
verupharma.com (VERU) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Veru Inc.|VERU - Long-Term Debt to Equity|Short-Term Debt to Capital Veru|VERU - Company Cumulative Debt|Debt to Book Capitalization Ratio Veru Corporation|VERU - Company Long-Term Loans and Borrowings|Company Current Liabilities Veru|Quick Liquidity Indicator verupharma.com
- business earnings and investment ratios data:
VERU - Final Profit|Projected Future Earnings Veru Inc.|VERU - Business Payback Period|Future Price to Earnings Veru Inc.|VERU - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Veru Corporation|VERU - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Veru|VERU - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months verupharma.com|VERU - Earnings per share growth in current year|Earnings growth forecast for next year Veru Inc.
Initial company analysis:VERU (Veru Pharma)
This indicator compares the total enterprise value to operating profit before depreciation and interest, allowing for an assessment of the real value of assets regardless of debt load and tax regime. Monitoring the EV/EBITDA valuation multiple serves as a stress-testing tool, confirming the resilience of Veru Inc. through high margins and the diversification of oncology drug sales, which mitigates the risks of regulatory restrictions.
Key competitors
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to EBITDA Ratio ERAS (Erasca, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DCTH (delcath.com)|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Aura Biosciences Inc (AURA) - Company Value to EBITDA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ARAY (Accuray, Inc.)|SLS (sellaslifesciences.com) - Enterprise Value to EBITDA Ratio|actuatetherapeutics.com (ACTU) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TARA|Total Company Value to Operating Income Before Depreciation Ratio Fate Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience WHWK|TCRX: Enterprise Value to Operating Income Before Depreciation|Champions Oncology Corp - EV/EBITDA Multiple|XBiotech Inc. (XBIT) - Enterprise Value to EBITDA Ratio|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OSTX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio RADX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ARTV|EV/EBITDA Multiple ANL|TPST - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|Business Value to Operating Income Before Depreciation RENB|MURA: Enterprise Value to EBITDA Ratio|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CytoMed Therapeutics Limited|CRIS (Curis Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Apollomics Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tharimmune, Inc. (THAR)|advanbiomed.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex)|CLDI - Enterprise Value to EBITDA Ratio|Sunshine Biopharma - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|purple-biotech.com - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio AONC|BGNE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CKPT|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|iCAD - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Ikena Oncology Inc. IKNA|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics)|MOR: EV/EBITDA Multiple|Company Value to EBITDA NAYA Biosciences Corp (NAYA)|Enterprise Value to EBITDA Ratio AAPGV
